News | May 18, 2025
Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
Shilpa’s product has been approved as a generic version to the innovator - Chantix Tablets, 0.5 mg and 1 mg, of PF Prism C.V. (PF Prism)
This program aims to develop a fully human monoclonal antibody against a novel immune checkpoint protein that enables T cell activation
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
The company has received the GMP Certification after successful closure of the inspection
Octreotide is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis
The inspection concluded with the issuance of Form 483 with four observations which are procedural in nature
GBM affects nearly 13,000 patients annually in the US and approximately 300,000 globally
This is used to treat central diabetes insipidus and bedwetting
Subscribe To Our Newsletter & Stay Updated
